Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Viral Infection
- Medical
- Diagnostic
- Test/Monitoring
- Drugs
- Vaccine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 381834
License Grant
University grants to the Australian Licensee, and any of its affiliates (i) an exclusive license under the patents to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the world (ii) a non-exclusive license to use Technical Information to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the world, and (iii) an exclusive license to use Materials to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the world.
University further granted Licensee the right to grant sublicenses. All rights granted to Licensee were reserved to University.
License Property
Product is for ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test for for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus.
Patent 62/431,550 'Differential Molecular Diagnostic Assay for Zika'
Field of Use
Field of use is for the testing of various viruses, including for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus.
The research program is in the field of CII-ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test, detect and differentiate the Zika virus, all Dengue virus serotypes, Chikungunya virus and West Nile virus. The key advantage of this diagnostic kit is the ability to detect and differentiate almost instantaneously the four viruses.
IPSCIO Record ID: 380354
License Grant
Licensor granted Licensee of the Cayman Islands a limited royalty bearing, non-exclusive, non-transferable, non-sublicensable, worldwide license under Licensor’s rights in their licensed patents to use certain Licensor products to make, have made, use, offer to sell, sell, have sold under our label and export certain licensed products relating to colorimetric LAMP for clinical diagnostic, investigational and research use.
License Property
Loop-Mediated Isothermal Amplification (the LAMP) – a patents to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid in-vitro diagnostic tests for the detection of a SARS-CoV-2. The main technical methods for COVID-19 testing include reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-PCR, serology test and antigen test. Nucleic acid amplification test, which includes RT-LAMP and RT-PCR, is the most extensively used in practice because of its high specificity, sensitivity and accuracy. The RT-LAMP technology was used to develop a viral RNA molecular test or nucleic acid amplification test for COVID-19.
Field of Use
Field of use is for the detection of a SARS-CoV-2 (COVID-19) virus.
IPSCIO Record ID: 364018
License Grant
University hereby grants to Licensee and Licensee hereby accepts an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights and a nonexclusive license to the know-how developed as of Effective Date by Natasa Strbo and Laura Romero (the Inventors) that is not encumbered by any third party rights, which is necessary to practice the Patent Rights to research, develop, make, have made, use, commercialize, market, promote, distribute, export, sell, offer to sell , or otherwise offer to dispose of Products in the Field of Use in the Territory and import the Product(s) and to practice the Process(es) described and/or claimed in the Patent Rights.
License Property
Technologies/Intellectual Property Provisional patent application entitled 'VECTORS AND VACCINE CELLS FOR IMMUNITY AGAINST ZIKA VIRUS' and filed 11-0ct-2016 with the US Patent and Trademark Office and assigned application number 62/406,506.
Field of Use
Field of Use shall mean GP96-lg-based vaccines against Zika Virus.
Zika Virus is a virus that is spread by mosquitoes.
IPSCIO Record ID: 380353
License Grant
Licensor granted Licensee of the Cayman Islands a worldwide exclusive license to develop, make, have made, use and have used, import, export and market certain licensed products in COVID-19 testing and diagnosis.
License Property
Licensed Products relate to a pending Chinese patent application No. CN202010232072.4 entitled “Primers for detecting novel coronavirus SAR-CoV-2, which causes COVID-19, and test kits, methods and applications thereof†and a pending U.K. patent application No. 2012480.6 entitled “Optimized primer design to stabilize the performance of RT-LAMP,†regarding the primer and molecular switch technologies that are integral to the nucleic acid amplification test.
Loop-Mediated Isothermal Amplification (the LAMP) – a patents to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid in-vitro diagnostic tests for the detection of a SARS-CoV-2. The main technical methods for COVID-19 testing include reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-PCR, serology test and antigen test. Nucleic acid amplification test, which includes RT-LAMP and RT-PCR, is the most extensively used in practice because of its high specificity, sensitivity and accuracy. The RT-LAMP technology was used to develop a viral RNA molecular test or nucleic acid amplification test for COVID-19.
Field of Use
Field of use is for the detection of a SARS-CoV-2 (COVID-19) virus.
IPSCIO Record ID: 380067
License Grant
The Japanese Licensor granted Licensee of the Cayman Islands a personal, non-transferable, non-assignable and non-exclusive licenses under certain patents, relating, in part to LAMP, to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid IVD tests for the detection of SARS-CoV-2 and to use, sell, offer for sale or otherwise dispose of the Licensor Licensed Products so made under Licensee’s own labels in the U.K. Pursuant to the Licensor Agreement, Licensee has the option to expand the license to the Licensor Licensed Patents for the Licensor Licensed Products to all countries of the world for additional one-off license fees.
License Property
Loop-Mediated Isothermal Amplification (the LAMP) – a patents to develop and make any reagent, product, kit, device, equipment, instrument and/or system for nucleic acid in-vitro diagnostic tests for the detection of a SARS-CoV-2. The main technical methods for COVID-19 testing include reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-PCR, serology test and antigen test. Nucleic acid amplification test, which includes RT-LAMP and RT-PCR, is the most extensively used in practice because of its high specificity, sensitivity and accuracy. The RT-LAMP technology was used to develop a viral RNA molecular test or nucleic acid amplification test for COVID-19.
Field of Use
Field of use is for the detection of a SARS-CoV-2 (COVID-19) virus.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
